Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoViricides has announced that its anti-HIV drug candidates demonstrated significant therapeutic efficacy in the recently completed preliminary animal studies.
Subscribe to our email newsletter
The studies were performed at a Bio-Safety Level 3 Laboratory (BSL-3) facility in Boston, Massachusetts. The company’s scientists are now designing the protocol for a follow up anti-HIV study to be performed at a major US government research facility. The company also said that animal studies for its drug candidates against bird flu (H5N1) are due to be scheduled at a major US government research facility.
Eugene Seymour, CEO of NanoViricides, said: “Dr Menon has indicated to us that the results of the study validate the company’s HivCide-I as a potential treatment for HIV/AIDS. Over the next several weeks, we expect to release additional study data.”